文献速递血栓与止血

Betrixaban延长预防对高龄内科患者的净临床获益

Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more.
PubMed 文献 · J Thromb Haemost · 2019-08-26

APEX试验亚组分析评估≥80岁急性内科病患者延长使用betrixaban的净临床获益。该亚组中VTE或大出血发生率betrixaban组7.0% vs 依诺肝素组8.4%,相对风险0.82(95%CI 0.62-1.10);但≥80岁患者主要疗效终点未达到。

要点

  • ≥80岁内科病患者VTE或大出血:betrixaban组7.0% vs 依诺肝素组8.4%,RR 0.82(95%CI 0.62-1.10)。
  • ≥80岁患者主要疗效终点(VTE)未达到。

核心结论

  • 在APEX试验≥80岁内科病患者中,延长betrixaban治疗使预设净临床获益降低,但主要疗效终点未达到。

研究设计与样本

  • APEX为随机双盲试验,急性内科病住院患者接受依诺肝素40 mg qd 10±4天或口服betrixaban 80 mg qd 35至42天。
  • 共纳入7513例患者,其中2781例(37%)年龄≥80岁。
  • 主要疗效终点为VTE,主要安全终点为大出血;净临床获益定义为VTE或大出血发生。

主要发现

  • ≥80岁亚组中,VTE或大出血发生率betrixaban组7.0% vs 依诺肝素组8.4%,相对风险0.82(95%CI 0.62-1.10)。
  • ≥80岁患者中betrixaban未达到主要疗效终点。

关键数值与推荐

  • 依诺肝素40 mg qd 10±4天;betrixaban 80 mg qd 35至42天。
  • 净临床获益相对风险0.82(95%CI 0.62-1.10)。

临床怎么用

  • ≥80岁急性内科病患者中,延长betrixaban治疗净临床获益降低,但主要疗效终点未达到,临床决策需权衡。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin. We aimed to assess the risk-benefit of betrixaban in patients aged ≥ 80 years enrolled in the APEX trial. METHODS: APEX was a randomized, double-blind trial in which patients hospitalized for acute medical illnesses received enoxaparin 40 mg qd for 10 ± 4 days or oral betrixaban 80 mg qd for 35 to 42 days. The primary efficacy outcome was VTE, the principal safety outcome was major bleeding. Net clinical benefit (NCB) was defined by the occurrence of VTE or major bleeding. RESULTS: Of 7513 patients enrolled in the APEX trial, 2781 (37%) were aged ≥ 80 years. In this subgroup, VTE or major bleeding occurred in 7.0% of betrixaban patients and in 8.4% of enoxaparin patients, for a relative risk in the NCB of 0.82 (95% confidence interval 0.62-1.10). The relative risk reduction obtained with betrixaban was similar between those aged ≥ 80 years and patients younger than 80 years (5.0% and 6.7%, respectively, NCB 0.75, 0.58-0.96, P = .024), with no significant interaction across age groups (P = .33). CONCLUSIONS: Event rates were higher in medically ill patients aged ≥ 80 years enrolled in the APEX study than in patients younger than 80 years. The predefined NCB was reduced with extended betrixaban therapy in both groups with no signs of age-related interactions. However, the primary efficacy endpoint was not achieved with betrixaban for patients 80 years of age or older.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Ageno W, Lopes RD, Yee MK, et al. Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. J Thromb Haemost. 2019. PMID: 31392827. doi:10.1111/jth.14600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。